USE OF GLP-1 RECEPTOR AGONISTS AND/OR SGLT-2 INHIBITORS AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE BEFORE AND AFTER REVASCULARIZATION IN A SINGLE-CENTER COHORT
Therapeutic Area: Peripheral Artery Disease Background: Diabetes mellitus (DM) is a major risk factor for peripheral artery disease (PAD). Patients with both PAD and DM have an increased risk of major adverse atherosclerotic events. GLP-1 RA and SGLT-2i are recommended to improve major adverse cardi...
Saved in:
Main Author: | Franck H. Azobou Tonleu, MD (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LIPID OPTIMIZATION AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE FOLLOWING REVASCULARIZATION IN A SINGLE-CENTER COHORT
by: Franck H. Azobou Tonleu, MD
Published: (2024) -
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023) -
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023) -
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesResearch in context
by: Luis A. Rodriguez, et al.
Published: (2024) -
Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
by: Alexander C. Falkentoft, et al.
Published: (2022)